Study design and participants
We analysed samples collected in a randomised, placebo-controlled, phase 1b–2a trial, which evaluated the safety, immunogenicity, and efficacy of AZD1222. Details of the multicentre study (COV005) done in South Africa have been described, including interim analysis of vaccine efficacy and immunogenicity through to 14 days following the two doses of AZD1222 in people living with HIV and HIV-negative individuals.